Tau-aggregation inhibitor therapy for Alzheimer's disease
about
Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's DiseaseMolecular Mechanisms in the Pathogenesis of Alzheimer's disease and Tauopathies-Prion-Like Seeded Aggregation and PhosphorylationDrug Development in Alzheimer's Disease: The Contribution of PET and SPECTCharacteristics of Tau and Its Ligands in PET ImagingTau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective StrategiesUpdate on Disease-Modifying/Preventive Therapies in Alzheimer’s DiseaseDiverse molecular targets for therapeutic strategies in Alzheimer's diseaseTherapeutic and diagnostic challenges for frontotemporal dementiaDifferent pathways of molecular pathophysiology underlie cognitive and motor tauopathy phenotypes in transgenic models for Alzheimer's disease and frontotemporal lobar degenerationPreventive methylene blue treatment preserves cognition in mice expressing full-length pro-aggregant human Tau.Caspase vinyl sulfone small molecule inhibitors prevent axonal degeneration in human neurons and reverse cognitive impairment in Caspase-6-overexpressing mice.Update on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease.RCAN1 regulates mitochondrial function and increases susceptibility to oxidative stress in mammalian cells.Early investigational drugs targeting tau protein for the treatment of Alzheimer's diseaseAmyloid β Protein and Alzheimer's Disease: When Computer Simulations Complement Experimental Studies.Structure and mechanism of action of tau aggregation inhibitors.Inhibition of tau aggregation by a rosamine derivative that blocks tau intermolecular disulfide cross-linking.Effects of oxidized and reduced forms of methylthioninium in two transgenic mouse tauopathy models.Nontoxic singlet oxygen generator as a therapeutic candidate for treating tauopathies.Loss of Microtubule-Associated Protein 2 Immunoreactivity Linked to Dendritic Spine Loss in SchizophreniaProtective Effect of Tat PTD-Hsp27 Fusion Protein on Tau Hyperphosphorylation Induced by Okadaic Acid in the Human Neuroblastoma Cell Line SH-SY5Y.Chitinase-3-like 1 protein (CHI3L1) locus influences cerebrospinal fluid levels of YKL-40.Mathematical model on Alzheimer's diseaseOligomeric α-synuclein and β-amyloid variants as potential biomarkers for Parkinson's and Alzheimer's diseasesInhibition of Both Hsp70 Activity and Tau Aggregation in Vitro Best Predicts Tau Lowering Activity of Small Molecules.Azaphilones inhibit tau aggregation and dissolve tau aggregates in vitroEfficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial.Tau acts as a mediator for Alzheimer's disease-related synaptic deficits.Protein phosphorylation in neurodegeneration: friend or foe?Clinical trials: past, current, and future for atypical Parkinsonian syndromes.Latest treatment options for Alzheimer's disease, Parkinson's disease dementia and dementia with Lewy bodies.Invited review: Animal models of tauopathies and their implications for research/translation into the clinic.Advances in the therapy of Alzheimer's disease: targeting amyloid beta and tau and perspectives for the future.Tau and neurodegenerative disease: the story so far.Tau-directed approaches for the treatment of Alzheimer's disease: focus on leuco-methylthioninium.Recent progress in repositioning Alzheimer's disease drugs based on a multitarget strategy.Genetics of Frontotemporal Lobar Degeneration: From the Bench to the Clinic.A curcumin-based molecular probe for near-infrared fluorescence imaging of tau fibrils in Alzheimer's disease.Methylene Blue Inhibits Caspases by Oxidation of the Catalytic Cysteine.Cellular Models of Aggregation-dependent Template-directed Proteolysis to Characterize Tau Aggregation Inhibitors for Treatment of Alzheimer Disease.
P2860
Q26739412-F6662DCD-FF0D-4941-BE82-793632C47BC1Q26748105-F6E6C116-F3C0-42B5-A066-BC23038E16AFQ26749755-CD9370E5-A8D3-4E77-AE99-2375318DE4C9Q26769952-7CDBA820-ED8C-406F-A55E-3853CD83AF93Q26769957-2F34EC1B-01FD-4B82-87AB-5E1A950EB762Q26778668-4D759577-9AD9-48D5-A2EA-CB331FCFB2AEQ26827193-59693795-477F-4DFA-A8B2-257AC8AE74E1Q26998919-69EF933D-A278-4E34-8C46-E5C2DBF96FA7Q30412009-12A72E7E-F86F-4EC3-8C72-11A1EC711C5AQ30649677-8AAF5EAE-5A4B-4331-B6D5-952CCEB15E8CQ30840106-8ACE0AD3-8C23-49B8-AEA4-DEC30EB00C14Q30845482-49ECB97A-3BC2-455C-82DD-286288875A9CQ33804508-46B51C1D-C479-4F47-9317-8B830E81663FQ33887379-A766B95D-FB4E-4C59-9D3A-FC1749681755Q33893017-DEE6E9B6-09B8-41CF-89C7-F17C977B0206Q34902096-27A9A43D-FFD5-4A77-8A74-CFCA0394EC79Q35185595-29C7EB08-24E2-4FE2-9617-B4D2396F6A29Q35558517-718E817A-7F38-4BC7-86F9-ACD3FA9BF532Q35669674-22AA094E-0BC4-4613-B1F0-729D6029BE2AQ35904717-88A0F119-D086-4DFC-AFD5-44B1AB13C05BQ36065433-B0E769B9-2918-4667-9F17-846EE3D39046Q36189198-7BCEC601-ECB4-4558-BF00-3406C2761FBFQ36198218-7B24D8A4-0D61-4E8F-A080-D46BC8C6F5C7Q36479597-3275EC0C-5CDC-4B29-BF81-9BE5CD3B3D59Q37417421-430E49E1-86A8-40C6-8A10-EB4D142985E5Q37419558-0A7ADFA7-2A0D-43C7-B35B-5AB49B3333CAQ37511619-01E65A5A-2E83-4223-8280-183E090EF3F1Q38203031-B814EE00-5DDD-4321-89AB-1E236A524040Q38214594-412E26CE-1A68-4ACB-ABEA-C45943D76D15Q38223118-B74E6E96-C2DC-4690-8CAB-6E8FA63D7A39Q38225930-5F80FA0A-2BAA-4E57-8471-99C273ADFB03Q38271896-431F2BC0-202A-40FD-B011-C9A7BA9A46ADQ38299414-5B2EFE21-1B40-4273-8B90-3F81AEAFC2AAQ38658752-CD93A8A1-AC0C-4284-8D97-6A0F8ED51A8CQ38715233-0C67ADD7-CB26-4D44-A249-A28AEF32DCC2Q38806779-949D31F2-3058-4D0E-BA0A-90F69B9A659FQ38814847-780480EF-816A-4606-96EC-56D9DC88A36AQ38826198-2671060D-71D7-424A-9596-B1DEEAC94A6AQ38833034-A66CCA13-C0C6-4A7C-88B3-A9E1D987EC2FQ38901388-C7E89037-EF44-4135-B9F8-55D2AF379F92
P2860
Tau-aggregation inhibitor therapy for Alzheimer's disease
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Tau-aggregation inhibitor therapy for Alzheimer's disease
@ast
Tau-aggregation inhibitor therapy for Alzheimer's disease
@en
Tau-aggregation inhibitor therapy for Alzheimer's disease
@en-gb
Tau-aggregation inhibitor therapy for Alzheimer's disease
@nl
type
label
Tau-aggregation inhibitor therapy for Alzheimer's disease
@ast
Tau-aggregation inhibitor therapy for Alzheimer's disease
@en
Tau-aggregation inhibitor therapy for Alzheimer's disease
@en-gb
Tau-aggregation inhibitor therapy for Alzheimer's disease
@nl
prefLabel
Tau-aggregation inhibitor therapy for Alzheimer's disease
@ast
Tau-aggregation inhibitor therapy for Alzheimer's disease
@en
Tau-aggregation inhibitor therapy for Alzheimer's disease
@en-gb
Tau-aggregation inhibitor therapy for Alzheimer's disease
@nl
P3181
P1476
Tau-aggregation inhibitor therapy for Alzheimer's disease
@en
P2093
Claude M Wischik
John M D Storey
P304
P3181
P356
10.1016/J.BCP.2013.12.008
P407
P577
2013-12-19T00:00:00Z